Drug Profile


Alternative Names: AN 021A; AN-021; DS 103282 CH; DS-103282; Sirdalud; Ternelin; Tizanidine hydrochloride; Zanaflex

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Acorda Therapeutics
  • Class Antispastics; Benzothiazoles; Imidazolines; Muscle relaxants; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Muscle spasticity
  • New Molecular Entity No

Highest Development Phases

  • Marketed Muscle spasticity
  • Discontinued Fibromyalgia; Migraine

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Muscle-spasticity(In adolescents, In children) in USA (PO, Capsule)
  • 01 May 2014 Acorda Therapeutics completes a phase II QTc-interval trial in Healthy volunteers in USA (NCT01839279)
  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top